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Abstract
Metastatic lung cancer encompasses a heterogenous group of patients in terms of burdens of disease, ranging from patients with extensive metastases to those
with a limited number of metastatic lesions (oligometastatic disease). Histopathological heterogeneity also exists within two broad categories, non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC), portraying different patterns and evolution of disease. Local consolidative therapy to the primary tumour
and metastatic sites, including surgery and/or radical dose radiotherapy, is increasingly being used to improve survival outcomes, particularly in the context of
oligometastatic disease, with or without the use of molecular targeted therapy and immunotherapy. Recently, randomised studies in oligometastatic NSCLC have
shown that local consolidative therapy may confer a survival advantage. This review explores whether treating just the primary tumour with radiotherapy may
similarly produce improved clinical outcomes. Such a treatment strategy may carry less potential toxicity than treating multiple sites upfront. The biological
rationale behind the potential benefits of treating just the primary in metastatic malignancy is discussed. The clinical evidence of such an approach across
tumour sites, such as breast and prostate cancer, is also explored. Then the review focuses on treating the primary in NSCLC and SCLC with radiotherapy, by first
exploring patterns of failure in metastatic NSCLC and second exploring evidence on survival outcomes from studies in metastatic NSCLC and SCLC. It is
challenging to draw conclusions on the clinical benefit of treating the primary cancer in isolation from the evidence available. This highlights the need to collect
data within the ongoing clinical trials on the clinical outcome and toxicity of radiotherapy delivery to primary thoracic disease specifically. This challenge also
identifies the need to design future clinical trials to produce randomised evidence for such an approach.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Most lung cancer patients still unfortunately present
with metastatic disease and despite recent advances in
molecular diagnostics and systemic anti-cancer therapies
(SACT), outcomes for many patients lag behind those of
patients with other common primary cancers [1]. The
traditional role of radiotherapy in this metastatic popula-
tion of patients has been for palliation of symptoms [2e4].
When considering palliative radiotherapy for the primary
lung tumour site, this is most commonly indicated for the
alleviation of local pain, control of bleeding or relief of
symptoms caused by obstruction or compression. A sys-
tematic review of 13 trials by Fairchild et al. [5] showed that
‘high dose palliation’ may confer a survival advantage
compared with lower doses. Higher dose (‘radical’) radio-
therapy tends to be considered for potentially curative
clinical scenarios in earlier stage lung cancer. However,d. This is an open access article under the CC BY-NC-ND license (http://
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demonstrating a role in disease modification to improve
outcomes in patients with metastatic lung cancer.Spectrum of Disease Burden and the
Biological State in Metastatic Lung Cancer
Metastatic lung cancer encompasses a heterogenous
group of patients ranging from patients with extensive
metastatic disease to those with limited metastatic disease
at a small number of sites (oligometastatic disease). The
most widely accepted ‘definition’ of the oligometastatic
state is  3e5 metastatic sites of disease [6]. With the
evolution of SACT and patients now receiving extended
periods of treatment, with targeted therapy or immuno-
therapy, further patterns of limited metastases are
described, such as: (i) oligoprogression, whereby metastatic
disease initially regresses with good response to SACT, and
then a small number of disease sites subsequently progress;
(ii) oligorecurrence, defined by metachronous recurrence at
a limited number of metastatic sites; and (iii) oligoresidual
disease, in which patients with metastatic disease experi-
ence a complete response other than a limited number of
persistent lesions [7]. Biologically, it is hypothesised that in
all of these circumstances these active sites may represent
emerging resistant clones and local therapy to these may be
a valuable therapeutic option.
The biological mechanisms leading to the development
of metastatic disease described by Hellman and Weichsel-
baum [8,9] suggest that metastatic potential develops in a
stepwise manner, such that there may be a phase, the oli-
gometastatic state, with limited further metastatic poten-
tial, when the disease may be amenable to cure with radical
treatment. Briefly, the ‘seed and soil’ hypothesis of meta-
static disease postulates that tumour cells acquire meta-
static potential by continuous genetic changes occurring
initially within the primary tumour [8,10]. With tumour
progression, this ‘seeding efficiency’ increases in proportion
to the number of tumour cells and tumour vascularity [11].
However, although the ‘seed and soil’ mechanism is oft-
cited to justify oligometastases as a distinct biological
state, several lines of data support a unique and dominant
role for the primary tumour, even in the setting of metas-
tases. For example, in certain tumour types, such as breast
cancer, the primary tumour may itself release factors that
create a dynamic and complex tumour microenvironment
or ‘soil’ that helps metastases thrive [12e14]. Under this
premise, there may be a role for focusing solely on the
primary tumour in specific clinical scenarios.
In contrast to these supporting data, separate pre-clinical
evidence suggests that the primary tumour may induce
‘dormancy’ in metastatic progression by the release of
inhibitory factors and, hence, surgical removal of, or radical
radiotherapy to, the primary tumour may cause a flare of
themetastatic disease. Folkman [15] discussed angiogenesis
as the basis of this effect, with angiostatin released from the
primary tumour inhibiting the development of metastases.
Other studies have discussed an alteration in the geneexpression and acquisition of a more invasive disease
phenotype following surgical removal of the primary
tumour and that trauma within the organ following inter-
ference/manipulation of the primary may induce factors
that enhance tumour growth [16,17]. Thus, pre-clinical data
are conflicting with regards to the basis for a distinctive role
for treatment of the primary site in metastatic disease.
Further complicating the issue is the increasing role of
immunotherapy in the context of lung cancer. Radiation
increases tumour antigen release by immunogenic cell
death and facilitates antigen presentation and subsequent
tumour T-cell infiltration. The abscopal effect, whereby
tumour regression occurs at an unirradiated site following
irradiation to a distant site of disease, has also been re-
ported rarely in the pre-immunotherapy era [18].
Combining radiotherapy with immunotherapy may poten-
tiate this effect and this has been shown at a pre-clinical
level, in case reports and suggested by recent and ongoing
randomised controlled studies, such as the PEMRO-RT trial
[19,20]. If this mechanism can be optimally exploited
through present or future checkpoint inhibitors, there may
be a biological rationale for irradiating the primary tumour
rather than metastatic sites when combined with immu-
notherapy, to target truncal neoantigen release from the
primary tumour rather than branch neoantigen release
from metastatic sites [21,22].Clinical Evidence for Consolidation
Treatment in Non-small Cell Lung Cancer
in Oligometastatic Disease
Several studies have provided evidence over the past
15e20 years that in selected non-small cell lung cancer
(NSCLC) patients with oligometastatic disease, treating the
metastatic sites of disease, such as resection of brain me-
tastases [23e25], local treatment of adrenal metastases
[23,26] or resection of pulmonary metastases [23], confers a
survival advantage. For example, ablative stereotactic radi-
osurgery (SRS) to solitary brain metastases in the RTOG
9508 study [27] was associated with a significantly
improved survival benefit from 4.9 to 6.5 months in 333
patients with metastatic disease. Sixty-four per cent of the
patients in this study had lung cancer. The results of such
studies have led to a change in practice. Currently, patients
with metastatic NSCLC with limited brain metastases that
are suitable for SRS and radically treatable extracranial
disease are offered SACT, SRS to brain metastases and
consideration of radical treatment to their intrathoracic
disease.
In the more recent era, the first randomised phase II trial
to report on outcomes in NSCLC patients with synchronous
oligometastatic disease (3 metastases) assessed 49 pa-
tients who did not progress after at least four cycles of
platinum-based chemotherapy or 3 months of epidermal
growth factor receptor (EGFR)- or anaplastic lymphoma
kinase (ALK)-targeted therapy [28,29]. Patients were rand-
omised to receive local consolidative therapy followed by
maintenance therapy or observation versus maintenance
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patients in the local consolidation therapy arm received
chemoradiotherapy (CRT), hypofractionated radiotherapy
or stereotactic radiotherapy (SBRT) rather than surgery for
the primary thoracic disease. The trial was closed early due
to the statistically significant median progression-free sur-
vival (PFS) advantage for the patients in the local consoli-
dation arm of 14.2 months compared with 4.4 months. A
recent update [29] showed a significantly longer median
overall survival for patients receiving local consolidation
therapy at 41.2 months compared with 17.0 months.
A subsequent randomised phase II trial showed similar
favourable outcomes. Twenty-nine patients with syn-
chronous oligometastatic disease (5 metastases) and
stable disease or a partial response after four to six cycles
of platinum-based chemotherapy were randomised to
receive SBRT to all metastatic disease sites and the primary
disease (SBRT or hypofractionated radiotherapy) followed
by maintenance chemotherapy or maintenance chemo-
therapy alone. Patients with EGFR or ALK mutations were
excluded. The trial was closed early due to significant PFS
benefit in the consolidative local therapy arm, with a
median PFS of 9.7 months compared with 3.5 months [30].
Additionally, of those patients who developed progressive
disease, no patient in the consolidation radiotherapy arm
had progression within a previous radiotherapy field, as
opposed to 70% of patients in the maintenance
chemotherapy-only arm having progressive disease in an
original site of disease.
In the metachronous setting, the phase II SABR-COMET
trial recruited patients with any primary histology, meta-
chronous oligometastatic disease and previously treated
primary disease. The trial has shown an increased overall
survival in patients who received stereotactic treatment to
sites of metastases compared with SACT alone, again sup-
porting the survival benefit of consolidation treatment in
the context of oligometastatic disease [31].
An important feature of all of these studies is that both
the primary tumour and the metastatic disease were
treated comprehensively. However, radical treatment of
the primary, and up to five sites of metastatic disease, may
be associated with additional toxicity over SACT alone. For
example, several SABR-related deaths were observed in
the SABR-COMET study [31], providing evidence that the
delivery of aggressive treatment is not a ‘free ride’ and
certainly less extensive treatment is associated with a
reduced incidence of adverse events. Furthermore, with
novel targeted agents and immunotherapy being increas-
ingly incorporated into the treatment paradigm, new
toxicities at distant sites that can be increase in the setting
of radiotherapy, such as gastrointestinal side toxicities and
central nervous system toxicities, will probably emerge,
will probably emerge. Thus, an important question going
forward in the design and analysis of studies examining
the role of surgery and radiation therapy in metastatic
disease is: ‘can treating just the primary tumour, which
usually constitutes the largest burden of disease and is
essentially the ‘source’ of metastatic potential, produce
similar outcome benefits to treating all lesions?’Evidence from Clinical Studies for
Treatment of the Primary Tumour in
Metastatic Disease
In metastatic breast cancer, a number of retrospective
studies have reported survival benefit with the treatment of
locoregional disease [32e34]. Meta-analyses have shown a
survival benefit with the surgical removal of primary
tumour [35,36]. One randomised controlled trial carried out
in India did not support this survival benefit after ran-
domising patients to locoregional or no locoregional treat-
ment after a response to SACT. However, in the trial, 31% of
the patients had HER-2-positive disease and 92% of those
patients did not receive HER-2-targeted therapy due to
financial constraints; therefore, the results should be
interpreted with caution [37]. A multicentre randomised
trial comparing locoregional treatment and systemic ther-
apy with systemic therapy alone in metastatic breast cancer
showed an increase in median survival at 40 months with
the addition of locoregional treatment [38].
In metastatic prostate cancer, a number of retrospective
studies have shown the survival benefit of treating the
primary tumour with local treatment [39,40]. More recently
it has been shown in a large randomised phase III trial that
treating the primary cancer with radical radiotherapy in
patients with metastatic prostate cancer significantly
improved PFS from 21 to 26 months, and the effect was
even more pronounced in patients with low metastatic
tumour burden [41].
Two randomised controlled trials have investigated the
effect of cytoreductive nephrectomy in renal cell carcinoma,
in addition to interferon-a2b. Both studies showed an in-
crease in PFS and overall survival with nephrectomy
[42,43]. More recent trials of systemic tyrosine kinase in-
hibitors (TKI) have shown no survival benefit with the
addition of nephrectomy in the CARMENA trial and with
immediate or deferred nephrectomy in the EORTC SURTIME
trial [44e46].Evidence from Clinical Studies for
Treatment of the Primary Tumour in
Metastatic Non-small Cell Lung Cancer
There is no randomised evidence with respect to treating
only the primary tumour in metastatic or oligometastatic
NSCLC. One can therefore explore the potential benefits of
treating solely the primary tumour, by looking at patterns of
disease failure (POF) in NSCLC and by assessing the available
retrospective evidence.
POF have been studied within a number of studies that
have shown that disease progression in NSCLC favours
known sites of disease [47e50]. This might suggest that
local control at these sites, including the primary tumour,
could be advantageous. For instance, for patients with
metastatic EGFR-mutant NSCLC on first-line TKI, the group
at Massachusetts General Hospital studied POF in 49 pa-
tients [48]. Twenty-three (47%) patients experienced
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48% of these patients, progression occurred only at the
primary site; for an additional 35% of these patients, pro-
gression occurred both at the primary and at other known
metastatic sites. It was also noted that regional nodal failure
only occurred in patients with previously known nodal
disease. In addition, failure at original sites of disease
occurred before the development of newmetastases, with a
median time to progression of 8.6 months for failure at
original sites of disease only compared with 12.3 months in
those with distant failure only. The primary tumour size
was significantly associated with failure at the primary site.
Interestingly, 10 patients (20%) would have been potentially
eligible for consolidation SBRT to all residual disease at their
maximal response to TKI. This study highlights that the
combination of TKI and local therapy may be disease
modifying for the mutation-positive patients, especially
upon the development of resistance to TKIs.
Prior to the widespread availability of third-generation
TKIs, a study of 64 EGFR-mutant patients progressing on
first-line TKI compared 39 patients continuing TKI beyond
progression with 25 patients who switched to chemo-
therapy [49]. Importantly, progression at the primary site of
disease occurred in most of the patients at the time of
further disease progression, 74% in the TKI group and 84% in
the chemotherapy group.
Although studies examining consolidative therapy in the
context of immunotherapy are continuing to emerge, in a
retrospective study of 26 patients with NSCLC who pro-
gressed in PD-1 axis inhibitor due to acquired resistance,
the 2-year overall survival from the time of acquired resis-
tance was 70% for the whole cohort but 93% for those who
received local therapy at sites of acquired resistance.
Moreover, a common site of progression was existing
thoracic lymph nodes [50], perhaps suggesting that con-
solidative treatment focusing on the primary tumour and
lymph nodes would have been impactful in improving
survival outcomes.
In contrast to these findings, Sheu et al. [51], in a
retrospective study of 90 oligometastatic NSCLC patients,
reported a POF, whereby 68% of all reported progres-
sions were with a new metastatic lesion. Interestingly,
however, almost half of those progressions (30% of all
observed progressions) were intracranial, whereas the
patient population investigated in this study included
59% of patients presenting with brain metastasis to start
with, with 49% presenting with intracranial metastases
only [51].
In the setting of local consolidative therapy, most studies
distinctly assessing the efficacy of targeting the primary
tumour have been retrospective in nature, thereby pri-
marily being hypothesis generating. In a retrospective study
of 186 synchronous oligometastatic NSCLC patients, those
who had local treatment to the primary tumour (surgical
resection or radical radiotherapy or SBRT) were compared
with those who did not. The median survival of patientswho received treatment to primary disease was longer (19
months) compared with that in patients who received no
primary definitive treatment (16 months) [52]. Another
study investigating the effect of thoracic treatment in 42
oligometastatic patients with solitary brain metastasis
treatedwith SRS showed a longermedian overall survival in
patients who received thoracic treatment (26.4 months)
defined as surgical, CRT or radiotherapy alone, compared
with those who did not (13.1 months) [53]. Chidel et al. [54]
also published a retrospective analysis of 33 NSCLC patients
with solitary brain metastasis who received either palliative
radiotherapy or no radiotherapy compared with radical
radiotherapy or surgery to the primary tumour. On multi-
variate analysis, aggressive thoracic treatment was a pre-
dictor of survival, with a median overall survival of 20.1
months compared with 3.5 months with no aggressive
thoracic treatment. The POF was predominantly at the pri-
mary tumour and the absence of aggressive thoracic treat-
ment was a predictor of such failure [54]. In another
retrospective study investigating oligometastatic patients
with brain-only metastases, aggressive treatment to the
primary tumour (surgery or radiotherapy/CRT) was an in-
dependent predictor for survival [55].
With regards to focusing on radiation therapy as the
consolidative paradigm, a retrospective study [56] included
29 patients with oligometastatic NCSLC who had definitive
treatment to the primary, with radical CRT or radiotherapy.
In a matched cohort comparison with patients who
received only chemotherapy, patients who received defin-
itive radiotherapy/CRT treatment had a statistically signifi-
cant increased median overall survival (22 months)
compared with those who did not (9 months). Moreover,
patients with thoracic treatment had a median time to local
failure of 18 months compared with 6 months in those who
had only chemotherapy.
Finally, a meta-analysis of seven retrospective studies on
668 patients with synchronous oligometastatic NSCLC, 34%
of whom had treatment to the primary with radiotherapy,
surgery or a combination, showed that thoracic treatment
was associated with a significant reduction in the risk of
death by 52% and significantly improved overall survival
[57]. A recent meta-analysis of 21 studies of oligometastatic
NSCLC patients selected specifically to investigate the out-
comes of patients receiving radiotherapy/CRT to the pri-
mary tumour, with or without local consolidative treatment
to metastatic disease, showed a median pooled overall
survival of 20.4 months and a pooled median PFS of 12
months [58]. Within this analysis, four studies with avail-
able data on the comparison of radiotherapy treatment to
the primary tumour versus no treatment were also ana-
lysed. This analysis showed significantly improved overall
survival and PFS in favour of radiotherapy treatment to the
primary tumour.
A number of ongoing studies are exploring consolidation
treatment in metastatic NSCLC, including treatment to the
primary tumour (Table 1).
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Table 1 (continued )
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ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IMRT, intensity-modulated radiotherapy; LCT, local consoli-
dation treatment (includes radiotherapy, surgery or a combination); OS, overall survival; PFS, progression-free survival; SABR, stereotactic
ablative radiotherapy; SACT, systemic anti-cancer treatment; SBRT, stereotactic body radiotherapy; SRS, stereotactic radiosurgery; TKI,
tyrosine kinase inhibitor.
* Each site may contain more than one metastatic lesion.
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Treatment of the Primary Tumour in
Metastatic Small Cell Lung Cancer
Although no randomised prospective evidence exists for
the treatment of solely locoregional disease in NSCLC, some
extrapolation can be made in the context of small cell lung
cancer (SCLC). In a randomised controlled study investi-
gating the effects of prophylactic cranial irradiation (PCI)
only, following systemic treatment, in extensive stage SCLC
disease showed that about 90% of patients developed early
intrathoracic disease progression [59]. In a recent phase III
randomised study, 498 patients with extensive stage SCLC
were randomised to receive consolidative thoracic radiation
and PCI versus PCI alone, following four to six cycles of
chemotherapy. It was found that consolidation thoracic
radiotherapy (30 Gy in 10 fractions) to the primary disease
and locoregional nodes conferred an overall survival
improvement at 2 years from 3% to 13%. In addition, isolated
intrathoracic progression was significantly less in the pa-
tients who received thoracic irradiation (19.8%) compared
with those who did not (46%), suggesting better local con-
trol, despite a ‘high palliative’ dose rather than a ‘radical’
dose [60]. In an earlier, single-site study, consolidation CRT
to thoracic disease with 54 Gy in 36 fractions and daily
carboplatin/etoposide chemotherapy was investigated in
extensive stage SCLC patients. The patients were rando-
mised provided they achieved a complete response to
extrathoracic disease and a partial or complete response to
intrathoracic disease, following systemic chemotherapy.
Randomisation was between an arm receiving CRT with
systemic chemotherapy and PCI and an arm receiving sys-
temic chemotherapy and PCI only. Patients receiving
thoracic treatment had a significantly improved overall
survival, from 28% to 38% at 2 years [61]. Thus, in SCLC ra-
diation therapy to the primary site seems to confer a small
but significant survival advantage in the setting of metas-
tases, even when consolidative treatment to metastatic
disease is not incorporated.Conclusions and Future Directions
In NSCLC, recent data have suggested that local consoli-
dation treatment to all sites of disease, including the pri-
mary tumour, may improve survival outcomes. In contrast,
no randomised evidence supports treating the primary
tumour in isolation in this clinical context. However, there is
biological and clinical evidence to suggest that treating the
primary tumour in metastatic disease, across tumour types,
may modify the evolution of disease and clinical outcomes.
In addition, in SCLC, delivery of thoracic radiotherapy was
associated with improved outcomes in the pre-
immunotherapy era. Furthermore, toxicity of radiation
therapy or surgery can be associated with high-grade and
even fatal adverse events, such that a toxicityeefficacy
trade-off exists when selecting appropriate patients for
comprehensive treatment. All of these lines of evidence
support a potential paradigm of select treatment of the
primary tumour in select patients with the goal of long-
term disease control.
Categorisation of appropriate patients will probably be
the greatest challenge in clearly isolating the role of primary
site treatment. Doing so may involve a number of factors,
including clinical and radiographic determinants, as well as
biomarkers from both the primary and metastatic sites, in
individual patients, that may facilitate the prioritisation of
treatment lesions. Correlates such as these will also provide
insight into the continued biological role of the primary
tumour in the development and treatment of metastatic
disease, which could have influential consequences in other
scientific arenas as well. Going forward, prospective studies
examining the role of local consolidative therapy should
specifically consider the effect of treating the primary dis-
ease. This analysis may be particularly important in the
group of patients experiencing long periods of stable dis-
ease on targeted therapies or immunotherapy, similar to the
concept proven in metastatic prostate cancer [41]. Indeed,
even if it is identified that only a small subset of patients can
be reliably spared treatment to metastatic sites due to
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cancer and the increasing role of radiation therapy and
surgery in this setting, the clinical and financial implications
of these findings could be substantial.Conflict of interest
F. McDonald reports trial grant funding from CRUK as
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